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Gastroenterological reflux disease and functional dyspepsia are usually treatable using
Western medical practices. Nonetheless, some cases present with intractable symptoms
that are not amenable to these therapies. Treatment with kampo, a traditional Japanese
medicine, recently has been proposed as an alternative therapy for use in combination
with the Western practices. In general, traditional Japanese medicines have been used
empirically for intractable symptoms correctively designated as “general malaises.”
Accumulating lines of evidence, including basic and clinical researches, have demonstrate
detailed mechanisms where traditional Japanese medicines exert pharmacological action
to improve symptoms. Therefore, traditional Japanese medicines have been gaining use by
various medical doctors as the specific modes of pharmacological action are recognized.
This review covers both the pharmacological functions and the clinical efficacies of
rikkunshito for use in treating disorders of the gastrointestinal tract.
Keywords: general malaises, gastroesophageal reflux diseases, functional dyspepsia, gastrointestinal motility,
acotiamide
INTRODUCTION
In Japan, an education in the practice of traditional Japanese
medicines was not popular in the standard educational sys-
tem until recently. This circumstance may be due to the fact
that the detailed mechanism(s) of the pharmacological action
of traditional Japanese medicines, including rikunshito, remains
unknown. Such mechanism(s) have been difficult to define, in
part because traditional Japanese medicines usually incorporate
a variety of components. As a result, many traditional medicines
have been used empirically that is, for the treatment of spe-
cific symptom. For instance, the traditional Japanese medicine,
kampo, often is prescribed (typically as combination therapy with
modern Western practices) for patients with medically unex-
plained physical symptoms or intractable gastrointestinal (GI)
symptoms. This patient group represents a distinct population
compared to that of patients with more typical and milder symp-
toms. Therefore kampo therapy, like many traditional Japanese
medicines falls within the field of experience-based medicine, in
contrast to that of evidence-based medicine. However, evidence
for the efficacy of traditional Japanese medicines, particularly for
rikkunshito, continues to accumulate (Tominaga and Arakawa,
2013). Hence, this review covers both basic and clinical evidences
of rikkunshito, including pharmacological functions and clinical
efficacies for the treatment and management of disorders of the
GI tract.
WHAT IS RIKKUNSHITO?
Rikkunshito first appeared in the Japanese literature in the
1500s. This agent has since become one of most famous and
prescribed medicines among the traditional medicines in Japan.
Rikkunshito is composed of 8 constituents: Glycyrrhizae radix,
Zingiberis rhizoma, Atractylodis lanceae rhizoma, Zizyphi fructus,
Aurantii nobilis pericarpium, Ginseng radix, Pinelliae tuber, and
Hoelen (Hattori et al., 2010). In recent times, analysis of the
components of rikkunshito has been actively performed using
high performance liquid chromatography. This work revealed that
rikkunshito contains several ingredients such as liquiritin apio-
side, liquiritin, liquiritigenin, isoliquiritin apioside, isoliquiritin,
isoliquiritigenin, glycyrrhizin, narirutin, and hesperidin (Endo
et al., 2014; Figure 1). Recently, hesperidin was shown to have the
highest potency (among these components) in a model of gastric
emptying delay. Together, these findings support the broad use of
rikkunshito for patients with dysfunction of the upper GI tract,
including abdominal bloating, discomfort, nausea, and anorexia.
BASIC PHARMACOLOGICAL FUNCTION OF RIKKUNSHITO:
PROTECTIVE EFFECT ON MUCOSAL INJURIES AND
PROKINETIC EFFECT ON GI MOTILITY
Gastric mucosa is sometimes injured by various factors such as
ethanol, non-steroidal anti-inflammatory drugs, systemic stress,
or Helicobacter pylori infection (Watanabe et al., 2000; Hamaguchi
et al., 2001; Takeuchi, 2012). Proton pump inhibitors (PPIs), his-
tamine type 2 blockers, or mucoprotective agents are effective for
treating such acute mucosal injuries (Arakawa et al., 1998; Yanaka
et al., 2007). Thus, Western medical practices are sufficient for the
treatment of such conditions. In addition to these conventional
drugs, traditional Japanese medicines, including rikkunshito, also
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FIGURE 1 | Pharmacological actions of rikkunshito on gastric motility.
(A) Three dimensional analysis for rikkunshito by high performance liquid
chromatography. (B) Effect of Rikkunshi-to on the decrease of the gastric
emptying rate induced by L-NNA. (C) Effect of Rikkunshi-to on adaptive
relaxation in isolated guinea pig stomachs. (D) Improvement in the 5-HT3
agonist [1-(3-chlorophenyl)biguanide]-induced delay in gastric emptying by
rikkunshito.
can protect against acute gastric mucosal injuries. Traditional
Japanese medicines, including rikkunshito, are equality effec-
tive in treating ethanol-induced acute gastric mucosal injuries,
through the amelioration of mucin content decrease of the gastric
mucosa (Goso et al., 1996). Such effect is also partially mediated
by nitric oxide (NO) but not by prostaglandins or sulfhydryls
(Arakawa et al., 1999). Therefore, rikkunshito exerts protective
effect against acute mucosal injuries in the rat model. However,
there is no definitive evidence for this pharmacological function
of rikkunshito under the acute and chronic conditions of the
human stomach.
Gastric motility, a physiological function of the GI tract, gen-
erally consists of three phases: reservoir, churning, and emptying.
The total coordination of these three phases is considered essential
to healthy GI physiology. Among the three phases needed for
gastric motility, gastric accommodation is considered to be the
most important. Gastric accommodation provides the reservoir
function, which originates in the proximal stomach and requires
the activity of the neuronal transmitter NO (Desai et al., 1991;
Uno et al., 1997). Rikkunshito is known to promote gastric
accommodation in isolated guinea pig stomach (Hayakawa et al.,
1999). Rikkunshito also relaxes the smooth muscles at the fun-
dus portion of stomach isolated from diabetic neuropathic rats
with gastric dysmotility (Kito and Suzuki, 2010). The observed
pharmacological functions also are induced by L-arginine, a sub-
strate of NO synthase that is also a component of rikkunshito.
Like prokinetic agents, rikkunshito counteracts the attenuation
of gastric dysmotility resulting from inhibition of NO synthesis
(Hayakawa et al., 1999; Kido et al., 2005). Furthermore, rikkun-
shito attenuates the delay of gastric emptying mediated by the
serotonin (5-HT) type 3 receptor, but does not counteract the
delay caused by activation of dopamine receptors (Tominaga
et al., 2009). Together, these findings indicate that rikkunshito
can ameliorate gastric dysmotility mediated by NO or 5-HT
pathways (Kido et al., 2005; Tominaga et al., 2009). Interestingly,
rikkunshito enhances endogenous ghrelin levels in plasma, and
regulates esophageal and gastric motilities (Takeda et al., 2008;
Yakabi et al., 2010). Ghrelin is known to have a strong orexigenic
effect (Kojima et al., 1999; Nakazato et al., 2001) and enhance GI
motility (Fujino et al., 2003; Inui et al., 2004; Yang et al., 2014).
It also has reported that rikkunshito attenuates impairment of
GI motility via dysfunction of ghrelin signaling in a rat model
of gastroesophageal reflux disease (GERD; Nahata et al., 2012).
More recently, Nahata et al. (2014) extended this work to a model
of gastric dysmotility. Those authors reported that acute restraint
stress caused plasma acylated/desacyl ghrelin imbalance and gas-
tric dysmotility in rat, and that exogenously administered acylated
ghrelin relieved the gastric dysfunction caused by this stress.
Rikkunshito was shown to enhance endogenous ghrelin signaling
and to provide similar relief of stress-induced gastric dysmotility
(Nahata et al., 2014). In a model of reflux esophagitis (RE),
rikkunshito also inhibited the activation of ERK1/2 and decreased
substance P and calcitonin gene-related peptide (CGRP) levels
in Th8–10 dorsal root ganglia (Kondo et al., 2014). This finding
may indicate that rikkunshito inhibits afferent neuronal activity
associated with visceral pain, ameliorating decreased voluntary
movement in this model. Together, these research data suggest
that rikkunshito may be a promising drug for the treatment of
GERD and functional dyspepsia (FD) in the clinic; this medicine’s
activity presumably is mediated by its pharmacological effects on
esophageal and gastric motilities (Figure 1).
CLINICAL EFFICACIES OF RIKKUNSHITO FOR UPPER GI
SYMPTOMS
TREATMENT WITH RIKKUNSHITO FOR GERD
The prevalence of obesity and metabolic syndrome in Japan
continues to rise. At the same time, the rate of H. pylori infection
in Japan is on the decrease. Under these circumstances, the
prevalence of GERD is expected to increase in Japan, as has been
seen in Western countries (Fujiwara and Arakawa, 2009; Fujikawa
et al., 2012). The reflux of gastric contents, consisting primarily
of gastric acid, is reported to be principal source of the patho-
genesis of GERD (Vakil et al., 2006). Additionally, transient lower
esophageal sphincter relaxation (TLESR) also is recognized to be
critical to the pathogenesis of GERD (Hershcovici et al., 2011).
Further GERD-associated factors include esophageal dysmotility,
hypersensitivity to gastric acid or bile acid within the lower
part of the esophagus, and gastric dysmotility affecting gastric
accommodation and emptying. PPIs have been established as
among the most effective drugs for treatment of GERD (Coté and
Howden, 2008). However, other drugs regulating the esophageal
motor functions also may prove useful in GERD treatment.
Based on the above-described data on rikkunshito, the agent is
a potential candidate treatment for patients with GERD, and so
has been the subjects of clinical research. In a study that used pH
multichannel intraluminal impedance monitoring, rikkunshito
increased esophageal clearance and decreased esophageal acid
exposure time, yielding relief of nausea symptoms in children
with GERD (Kawahara et al., 2014). This traditional medicine
also has been reported to relieve heartburn and acid regurgitation
(Hiyama et al., 2008).
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In our own clinical work, we often encounter adult patients
with PPI-refractory GERD, although PPIs typically are very effec-
tive for treating this disease. Anecdotally, PPI-refractory GERD
often is observed in patients lacking erosions of the esophageal
mucosa (non-erosive reflux disease, NERD). In the GERD 4
study (a randomized, parallel comparative study of PPI-refractory
patients with GERD), combined treatment with rikkunshito and
standard-dose rabeprazole showed an efficacy similar to that
of double-dose PPI treatment (Tominaga et al., 2012). In a
subsequent study (G-PRIDE: A randomized, placebo-controlled,
double-blind clinical trial of rikkunshito for patients with NERD
refractory to PPI), rikkunshito improved psychological qual-
ity of life (QOL) compared to the placebo control (Tominaga
et al., 2014). In addition, among secondary endpoints, significant
efficacy of rikkunshito was observed for acid-related dyspeptic
symptoms, especially among non-obese patients, women, and
the elderly. Subclass analysis of the elderly PPI-refractory NERD
patients in the G-PRIDE study also showed that rikkunshito
significantly improved total and acid-related dysmotility scores
after the 8-week treatment interval compared to placebo. In
addition, 8-week combination therapy with rikkunshito signifi-
cantly improved symptoms of abdominal bloating, “heaviness” of
the stomach, sick feeling after meals, and heartburn after meals
(Sakata et al., 2014). Beyond standard symptoms, patients with
GERD also are known to exhibit extra-esophageal symptoms.
Interestingly, rikkunshito has been shown to be effective for
patients with globus sensation, an effect mediated by attenuation
of delayed gastric emptying (Tokashiki et al., 2013).
On the other hand, rikkunshito also has activities distinct from
prokinetic functions. In a rat RE model, rikkunshito was shown
to promote tight junction protein formation and to contribute to
the repair of the dilation of intercellular spaces in the epithelial
mucosa (Miwa et al., 2010). As with gastric acid, bile acid reflux
is important for mucosal hypersensitivity in the pathogenesis of
PPI-refractory GERD. Rikkunshito is reported to exhibit potent
and differential absorption of bile salts (Araki et al., 2012).
Notably, these findings suggest that rikkunshito may attenuate
mucosal hypersensitivity to gastric acid or bile acid. These distinct
pharmacological functions of rikkunshito may be a mechanism
for relief of GERD symptoms in PPI-refractory NERD patients.
Currently, long-term maintenance and enhanced therapies are
recommended as future therapeutic regimens for PPI-refractory
GERD patients (Kinoshita et al., 2012). Based upon these evi-
dences, treatment regiments incorporating rikkunshito may be
beneficial to GERD patients, particularly for PPI-refractory cases.
(Figure 2).
TREATMENT WITH RIKKUNSHITO FOR FD
Functional dyspepsia presents as symptomatic gastritis. Patho-
genesis of this disease is similar to that of chronic gastritis
associated with H. pylori infection. Therefore, FD recently has
been categorized as a disease distinct from chronic gastritis,
and therefore has been classified as a member of the functional
gastrointestinal disorders (FGIDs). According to the 2006 Rome
III criteria (Drossman, 2006), the diagnosis of FGIDs is indicated
in FD patients exhibiting any of four symptoms (epigastric pain,
epigastric burning, postprandial fullness, or early satiety) orig-
FIGURE 2 | Pharmaceutical efficacies of rikkunshito for GERD
treatment.
inating from the gastroduodenal tract without evident organic
injuries. These symptoms often persist even after a variety of
treatments, decreasing the QOL in patients with FD (Kinoshita
et al., 2011). The pathophysiology of FD can reflect disorders of
GI motility (Tominaga et al., 2008), acid secretion (el-Omar et al.,
1995; Iwakiri et al., 2013), visceral hypersensitivity (Farré et al.,
2013), H. pylori infection (Mönnikes et al., 2005), psychological
factors (Tominaga et al., 2007; Ochi et al., 2008), and imbalance of
the autonomic nervous system (ANS; Park et al., 2001). Of these
factors, GI dysmotility has been most frequently associated with
the pathogenesis of FD; however, this emphasis may reflect the
relative ease of evaluating the physiological function of the GI
tract in patients with FD. Gastric motility, notably its delay, has
been a focus of evaluation in the pathogenesis of FD (Brun and
Kuo, 2010). However, total coordination of gastric motility needs
to be further elucidated for its potential role in the pathogenesis
of FD. Indeed, disorder of gastric accommodation may cause
epigastric discomfort, early satiety, and bloating in patients with
FD (Bredenoord et al., 2003). Previously, we have reported that
the impairment of gastric accommodation is associated with
a delay in gastric emptying, resulting in dyspeptic symptoms
(Tominaga et al., 2008). Recently, the high efficacy of acotiamide
was demonstrated for treatment of dyspeptic symptoms in FD
patients, an effect mediated by improvement of gastric accommo-
dation (Matsueda et al., 2012; Kusunoki et al., 2012). Based on
the results of various clinical trials, only acid suppressant drugs,
prokinetic drugs, and eradication therapy for H. pylori have (until
recently) been strongly recommended in Japan for treatment of
FD. In this context, rikkunshito has been reported to ameliorate
the delay in gastric emptying in patients with non-ulcer dyspepsia
(NUD; Tatsuta and Iishi, 1993). The same report indicated that
rikkunshito also alleviated various upper GI symptoms in patients
with NUD (Tatsuta and Iishi, 1993). Moreover, rikkunshito has
demonstrated efficacy for attenuation of impaired gastric accom-
modation and gastric motility (Kusunoki et al., 2010). Sepa-
rate from stress’ effects on gastric motility in the pathogenesis
of FD, physical and psychological stresses often cause gastric
hypersensitivity to stimulation by mechanical balloon distension.
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Stress-induced gastric hypersensitivity and/or changes in gastric
wall tone (as assessed by gastric barostat method) were relieved
by rikkunshito (Shiratori et al., 2011). In a separate human study
comparing rikkunshito and domperidone, rikkunshito improved
symptoms of patients with FD and increased plasma ghrelin
levels (Arai et al., 2012). Rikkunshito was shown to amelio-
rate delayed gastric emptying in severely handicapped patients
(Kawahara et al., 2009) and to improve gastric myoelectric activ-
ity in post-operative dyspeptic children after GI surgery (Yagi
et al., 2004). These findings suggest that rikkunshito affects some
inflammatory and/or neuroendocrinal mediators as well as gastric
sensorimotor function, and improves dyspeptic symptoms of
FD. Apart from FD, GI symptoms sometimes occur after endo-
scopic treatment. Combination therapy with rikkunshito and
PPI after endoscopic submucosal dissection alleviated abdominal
pain symptoms (Uehara et al., 2013). Recently, a randomized
clinical trial using rikkunshito was performed for FD. Eight-
week treatment with rikkunshito was tended to be effective for
FD, as determined by global patient assessment (Suzuki et al.,
2014). Thus, rikkunshito is a potential candidate for the clinical
treatment of FD.
In conclusion, rikkunshtio is considered “complementary”
(non-mainstream) medicine for treatment of GI diseases such as
GERD and FD. However, rikkunshito frequently is prescribed for
patients with diverse GI tract disorders. Combination treatments
using modern Western and traditional Japanese medicines should
be considered, especially in patients presenting with intractable
symptioms, including general malaises.
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